title: Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases.
abstract: BACKGROUND
  Inflammatory bowel diseases (IBD) are characterized by periods of remission with recurrent episodes of symptom exacerbation because of acute intestinal inflammation, which is correctly evaluated by endoscopy with biopsy sampling. However, many surrogate markers of intestinal inflammation, including fecal calprotectin (FC), are detected as potential predictors of mucosal inflammation in IBD patients. The aim of our study was to retrospectively assess the clinical efficacy of the calprotectin assay in determining histological relapses of pediatric IBD patients.
  
  
  METHODS
  We retrospectively reviewed the histological examinations, clinical records, and FC values of patients who had undergone colonoscopy at our hospital over an 8-year period, from December 31, 1998, to December 31, 2006. Only patients with a first histological examination showing a quiescent IBD who submitted to a second histological examination during the next 3 years were selected.
  
  
  RESULTS
  Seventy-three IBD patients, all with a first biopsy showing a quiescent IBD, were studied; at the second histological examination, 32 presented with relapse and 41 presented with remission. Relapsed patients showed significantly increased FC levels compared with nonrelapsed patients. A FC value of 275 mug/g achieved sensitivity and negative predictive value of 97% and specificity and positive predictive value of 85% in predicting histological relapse.
  
  
  CONCLUSIONS
  FC seems to be a direct measure of intestinal inflammation and therefore a good marker of the risk of histological relapse in pediatric IBD patients. The application of this test in clinical practice may enable the avoidance of invasive tests as well as targeting treatment.
authors.affiliation: Gastroenterology Unit, Bambino Gesù Children's Hospital, Rome, Italy. diamanti@opbg.net
authors.forename: A
authors.initials: A
authors.lastname: Diamanti
authors.forename: F
authors.initials: F
authors.lastname: Colistro
authors.forename: M S
authors.initials: MS
authors.lastname: Basso
authors.forename: B
authors.initials: B
authors.lastname: Papadatou
authors.forename: P
authors.initials: P
authors.lastname: Francalanci
authors.forename: F
authors.initials: F
authors.lastname: Bracci
authors.forename: M
authors.initials: M
authors.lastname: Muraca
authors.forename: D
authors.initials: D
authors.lastname: Knafelz
authors.forename: P
authors.initials: P
authors.lastname: De Angelis
authors.forename: M
authors.initials: M
authors.lastname: Castro
mesh_terms: D000293:Adolescent; D001681:Biological Assay; D015415:Biomarkers; D002648:Child; D002675:Child, Preschool; D003113:Colonoscopy; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005243:Feces / Q000737:chemistry*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000378:metabolism*; D039841:Leukocyte L1 Antigen Complex / Q000378:metabolism*; D008297:Male; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies
chemical_list: D015415:Biomarkers; D039841:Leukocyte L1 Antigen Complex